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Positive autoregulation of GDNF levels in the ventral
tegmental area mediates long-lasting inhibition of
excessive alcohol consumption
S Barak1,2, S Ahmadiantehrani1,3, V Kharazia1 and D Ron1,2,3
Glial cell line-derived neurotrophic factor (GDNF) is an essential growth factor for the survival and maintenance of the midbrain
dopaminergic (DA-ergic) neurons. Activation of the GDNF pathway in the ventral tegmental area (VTA), where the GDNF
receptors are expressed, produces a long-lasting suppression of excessive alcohol consumption in rats. Previous studies
conducted in the DA-ergic-like cells, SHSY5Y, revealed that GDNF positively regulates its own expression, leading to a long-
lasting activation of the GDNF signaling pathway. Here we determined whether GDNF activates a positive autoregulatory
feedback loop in vivo within the VTA, and if so, whether this mechanism underlies the long-lasting suppressive effects of the
growth factor on excessive alcohol consumption. We found that a single infusion of recombinant GDNF (rGDNF; 10 lg) into the
VTA induces a long-lasting local increase in GDNF mRNA and protein levels, which depends upon de novo transcription and
translation of the polypeptide. Importantly, we report that the GDNF-mediated positive autoregulatory feedback loop accounts for
the long-lasting inhibitory actions of GDNF in the VTA on excessive alcohol consumption. Specifically, the long-lasting
suppressive effects of a single rGDNF infusion into the VTA on excessive alcohol consumption were prevented when protein
synthesis was inhibited, as well as when the upregulation of GDNF expression was prevented using short hairpin RNA to focally
knock down GDNF mRNA in the VTA. Our results could have implications for the development of long-lasting treatments for
disorders in which GDNF has a beneficial role, including drug addiction, chronic stress and Parkinson’s disease.
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Introduction
Glial cell line-derived neurotrophic factor (GDNF) is a
secreted growth factor that was initially identified in a glial-
derived cell line1 GDNF is expressed throughout the central
nervous system during development, and high levels ofGDNF
mRNA are present in the adult neurons in brain regions such
as the striatum, thalamus, cortex and hippocampus.2 In the
mesolimbic/nigrostriatal systems, GDNF is produced in
striatal neurons3,4 and is retrogradely transported by dopa-
minergic (DA-ergic) neurons to the substantia nigra5,6 and the
ventral tegmental area (VTA),7 where the GDNF receptors,
GFRa1 and Ret, are highly expressed.8–10 Ligation of GDNF
to GFRa1 leads to the recruitment and activation of the
receptor tyrosine kinase Ret, and to the consequent activation
of several signaling cascades, including the mitogen-
activated protein kinase pathway.2,11
GDNF is an important factor for the survival, regeneration
and maintenance of DA-ergic midbrain neurons,1,2 and an
increase in the GDNF levels has been suggested to be
beneficial for Parkinson’s disease2,12 and chronic stress.13
Moreover, activation of the GDNF pathway in the VTA has
recently been suggested to negatively regulate the intake of
drugs of abuse, including alcohol.14,15 Specifically for alcohol,
activation of the GDNF signaling pathway in the VTA results in
a fast (minutes), but also a very sustained (at least 48 h),
reduction in excessive, ‘binge-like,’ alcohol consumption in
rats.16,17 The rapid actions of GDNF aremediated by the rapid
stimulation of VTA DA-ergic neurons and the reversal of
alcohol-induced DA deficiency in the nucleus accumbens
(NAc).7,18 However, the long-lasting suppressive actions of
GDNF on alcohol consumption are not likely to bemediated by
the recombinant growth factor, which degrades within several
hours. Therefore, the mechanism mediating these protracted
effects is unknown.
Treatment of the DA-ergic-like SHSY5Y cell line with
GDNF induces a long-lasting increase in the growth factor’s
own expression, which subsequently causes a sustained
activation of its signaling pathway.19 Specifically, a short
exposure of SHSY5Y cells with recombinant GDNF (rGDNF)
leads to a prolonged increase in the levels of the growth
factor, and to the consequent long-lasting activation of Ret
and the Ret-mediated activation of the mitogen-activated
protein kinase extracellular-regulated protein kinase 1/2
(ERK1/2).19
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Here we show that the maintenance of the suppressive
effects of a single infusion of rGDNF into the VTA on
excessive alcohol consumption are mediated by the capacity
of GDNF to positively and sustainably autoregulate its own
mRNA and protein levels in an autocrine manner.
Materials and methods
A detailed description of the methods and procedures that
appear below, as well as information about reagents,
preparation of GDNF short hairpin RNA recombinant adeno-
virus, quantitative/semi-quantitative reverse transcription
PCR, western blot analysis, drug administration, immunohis-
tochemistry and histology can be found in the Supplementary
Information.
Animals. Male Long–Evans rats (Harlan, Indianapolis, IN,
USA); 400–450 g at the time of the surgery) were housed
under a 12-h light/dark cycle (lights on at 0700h) with food
and water available ad libitum. All animal procedures in this
report were approved by the Gallo Center Institutional Animal
Care and Use Committee and were conducted in agreement
with the Guide for the Care and Use of Laboratory Animals,
National Research Council, 1996.
Intracranial infusion of rGDNF and adenovirus (AdV)-
shGDNF
Intra-VTA rGDNF infusion. Surgery, cannula implantation
and infusion of rGDNF (10 mg per side in 1 ml) into the VTA
were conducted as previously described.17 See Supplemen-
tary Information for detailed information.
Intra-VTA AdV-shGDNF infusion. Infusion of viruses
(AdV-shGDNF or Adv-Scrambled (SCR), 1.3 108 TUml1)
into the VTA was conducted similarly to our previous report.7
See Supplementary Information for detailed information.
Intermittent-access to 20% alcohol in the two-bottle
choice drinking procedure. The intermittent access to
alcohol procedure was performed as previously
described.16,17 Specifically, animals were given 24 h of
concurrent access to one bottle of 20% volume/volume
alcohol in tap water and one bottle of water, starting at 1100 h
on Monday, Wednesday and Friday, with 24 or 48 h of
alcohol-deprivation periods in between the alcohol-drinking
sessions. The water and alcohol bottles were weighed after
30min, 4 and 24 h of access. Surgery, virus infusion and
microinjection procedures started after 21 alcohol access
sessions, when rats maintained a stable baseline of alcohol
consumption of 5.5–6 g kg1 per 24 h. See Supplementary
Information for full details.
Statistical analysis. Data generated from reverse
transcription-PCR experiments were analyzed using paired
t-test or one- or two-way analysis of variance with/without
repeated measures, as specified. Alcohol drinking
experiments were conducted in a within-subjects design or
mixed-model design. Alcohol preference was calculated as
the percentage of alcohol solution consumed relative to total
fluid intake (alcoholþwater). Student Newman–Keuls post-
hoc analysis was used where indicated. See Supplementary
Information for full details.
Results
GDNF induces its own sustained expression and
produces a long-term activation of the ERK1/2 pathway
in the VTA. As the GDNF receptors GFRa1 and Ret are
highly expressed in the VTA,8–10,20,21 we tested whether
GDNF activates a positive autoregulatory loop in vivo in this
brain region. To do so, rGDNF (10 mg) was infused into one
side of the VTA and vehicle into the other side. The VTA was
dissected 12, 24 or 48 h later and the expression levels of
GDNF were measured. As shown in Figure 1a–c, GDNF
mRNA levels were significantly higher in the GDNF-infused
side at all three time points, suggesting that the activation
of the GDNF-mediated signaling pathway in the VTA leads
to a sustained increase in GDNF mRNA that lasts for at
least 48 h.
Next, we tested whether a single application of rGDNF in
the VTA results in a long-lasting activation of the GDNF-
mediated signaling pathway. Rats were infused with the
recombinant growth factor (10 mg) into one side of the VTA
and vehicle into the other side. Twenty-four hours later,
the immunoreactivity of phosphorylated and thus activated
ERK1/2 (pERK1/2) was measured. As shown in Figure 1d,
remarkably higher levels of pERK1/2 were detected in the
rGDNF-infused side, predominantly in DA-ergic (tyrosine
hydroxylase-positive) neurons, as compared with the vehi-
cle-infused side. These results suggest that a single infusion
of rGDNF into the VTA leads to an increase in the level of
GDNF and to a long-lasting activation of the GDNF-mediated
ERK1/2 activation in the VTA.
GDNF-mediated upregulation of GDNF levels in the VTA
requires de novo protein synthesis. The results above
suggest that the long-lasting increase in GDNF levels in the
VTA is due to the maintenance of a positive autoregulatory
feedback loop in which GDNF upregulates its own
expression. If this is the case, then the maintenance of this
loop should depend on de novo protein synthesis. To test this
possibility, the protein synthesis inhibitor cycloheximide
Figure 1 A single infusion of recombinant glial cell line-derived neurotrophic factor (rGDNF) into the ventral tegmental area (VTA) produces a sustained induction of GDNF
expression and phosphorylation of extracellular-regulated protein kinase 1/2 (ERK1/2). rGDNF (10 mg, unilateral) or vehicle was infused into the VTA of rats 12 h (a), 24 h (b)
or 48 h (c) before the VTA dissection. GDNF and GAPDH mRNA levels were determined using semi-quantitative reverse transcription PCR. GAPDH levels were measured to
standardize sample loading. Data are expressed as mean±s.e.m. of GDNF/GAPDH expression (t’s43.50, *Po0.05; n¼ 3–5). (d) Shown is a dual-channel
immunofluorescence for phospho-ERK1/2 (p-ERK1/2, red), tyrosine hydroxylase (TH, a marker for dopaminergic neurons, green), and overlay (yellow). Left panel: images
depict ERK1/2 phosphorylation in the midbrain 24 h after rGDNF (left brain side) or PBS (right side) infusion into the VTA. Images are representative of results from four rats
(six sections per rat), scale bar: 500mm. Right panel: magnified image of the VTA infused with rGDNF, as marked in a white square in Figure 2a. The arrowheads point to cells
immunostained for both p-ERK1/2 and TH, scale bar: 50 mm.
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(CHX; 2mgkg1, i.p.)22,23 or vehicle was administered to rats
50min before and 3 h after a unilateral intra-VTA rGDNF
infusion, and the VTA was dissected 24 or 48 h after rGDNF
infusion. CHX was administered twice at this interval to
assure efficient inhibition of protein synthesis of at least
6–8 h.24 As depicted in Figure 2a, in control rats, we
observed a robust increase in GDNF mRNA after 48 h in
the side of the VTA that was infused with rGDNF, as
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compared with the vehicle-infused VTA side. However, CHX
pretreatment abolished these effects (Figure 2a). To confirm
that a single infusion of rGDNF leads to a de novo synthesis
of the endogenous protein, we measured GDNF levels in the
VTA in the absence and presence of CHX. As shown in
Figure 2b, infusion of the growth factor into the VTA
produced a significant increase in the level of the
protein, which was detected even 24 h later, and was
abolished in response to CHX treatment. Together, these
results suggest that inhibition of de novo protein synthesis
disrupts the positive feedback loop of GDNF expression and
signaling.
Next, we examined the consequences of downregulation of
the GDNF transcript on the long-lasting increase in GDNF
levels induced by a single administration of the recombinant
polypeptide. To prevent the induction of GDNF mRNA, we
used adenoviral-mediated gene delivery of short hairpin RNA,
targetingGDNFmRNA (AdV-shGDNF),7 to specifically down-
regulate the level of the growth factor in the VTA of rats. This
virus also expresses GFP, which was used to detect the
infection locus. As shown in Supplementary Figure 1, AdV-
shGDNF infected DA-ergic (tyrosine hydroxylase-positive)
neurons in the VTA and induced B40% decrease in GDNF
mRNA expression in this brain region (day 14). Next, we
unilaterally infused rGDNF (10 mg) and vehicle into the VTA of
rats that were infected with AdV-shGDNF or AdV-shSCR
control in the VTA, 14 days earlier. We then examined the
levels of GDNF 24 h after the infusion of the recombinant
Figure 2 Recombinant glial cell line-derived neurotrophic factor (rGDNF)-mediated upregulation of GDNF mRNA and protein requires de novo protein translation.
rGDNF (10mg, unilateral) or vehicle was infused into the ventral tegmental area (VTA) of rats 48 h (a) or 24 h (b) before VTA dissection. Cycloheximide (CHX; 2 mg kg1, i.p.)
was administered 50 min before and 3 h after rGDNF infusion. CHX was administered twice at these intervals to provide efficient inhibition of protein synthesis for at
least 6–8 h.24 (a) GDNF and GAPDH mRNA levels were determined using semi-quantitative reverse transcription PCR. Data are expressed as mean±s.e.m. of
GDNF/GAPDH levels (main effects of CHX pretreatment (F (1,6)¼ 67.03; Po0.0002) and rGDNF infusion (F (1,6)¼ 156.88; Po0.0001), and a significant interaction
(F (1,6)¼ 101.09; Po0.0001). Post-hoc comparison: a significant difference between the rGDNF- and the vehicle-infused sides in rats that were pretreated with
vehicle, but not in CHX-pretreated rats; **Po0.001; n¼ 4). (b) GDNF and GAPDH protein levels were determined using western blot analysis. Data are expressed as
mean±s.e.m. of GDNF/GAPDH levels (main effects of CHX pretreatment (F (1,6)¼ 171.01; Po0.0001) and rGDNF infusion (F (1,6)¼ 281.47; Po0.0001),
and a significant interaction (F (1,6)¼ 279.17; Po0.0001). Post-hoc comparison: a significant difference between the rGDNF- and the vehicle-infused sides in rats
that were pretreated with vehicle, but not in CHX-pretreated rats; **Po0.001; n¼ 4). (c) Adenovirus shGDNF (AdV-shGDNF) or AdV-shSCR (1.2ml per
side, 1.3 108 TU ml1) was infused into the VTA of rats. rGDNF was infused into the VTA 14 days after virus infection. The VTA was dissected 24 h later and
GDNF mRNA levels were quantified by real-time reverse transcription PCR. Data are expressed as mean±s.e.m. of GDNF/GAPDH expression (main effects of
viral infection (F (1,12)¼ 61.19, Po0.0001) and rGDNF infusion (F (1,12)¼ 16.57, Po0.002), and a significant interaction (F (1,12)¼ 18.37, Po0.002);
post-hoc comparisons: a significant difference between rGDNF- and vehicle-infused VTA in the AdV-shSCR-infected rats (**Po0.001), but not in the AdV-shGDNF-infected
rats; n¼ 3–4).
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growth factor, and found that AdV-shGDNF-mediated down-
regulation of the endogenous gene is sufficient to disrupt the
positive autoregulatory loop initiated by exogenous rGDNF
(Figure 2c).
Inhibition of protein synthesis prevents the long-lasting,
but not the acute, effects of GDNF on alcohol
consumption. Next, we tested whether the activation of the
positive autoregulatory feedback loop of GDNF signaling in the
VTA underlies the ability of the growth factor to induce a long-
lasting decrease in alcohol intake. To do so, rats were trained
in an intermittent access to 20% alcohol, two-bottle choice
procedure for 7 weeks to obtain a baseline level of alcohol
intake of 5.5–6g kg1 per 24h. This procedure generates a
blood alcohol concentration of 80.9±7.2mg%,16 which
corresponds to the blood alcohol concentration values that
are defined by the National Institute on Alcohol Abuse and
Alcoholism as binge drinking in humans.25 We then inhibited
protein synthesis by administering CHX (2mgkg1, i.p.) or
vehicle 1h before and 3h after the beginning of the drinking
session, and rGDNF or vehicle was bilaterally infused into the
VTA 10min before the beginning of the drinking session
(Figure 3a). The immediate effects of GDNF on alcohol
drinking were assessed by measuring alcohol consumption
during the first 30min of the drinking session, whereas
the long-lasting effects were determined by measuring
consumption during the period of 4–24h after the beginning
of the drinking session.
As previously reported,16 a single infusion of rGDNF into the
VTA produced both a rapid (30min) and a long-lasting
(4–24 h) reduction in alcohol intake (Figure 3b and Supple-
mentary Figure 2A). CHX on its own did not alter the intake of
alcohol (Figure 3b and c) or total fluid (Supplementary
Figure 2C), and had no effect on the GDNF-mediated
suppression of alcohol consumption during the first 30min
(Figure 3b). In contrast, CHX pretreatment blocked the long-
lasting (4–24 h) actions of GDNF on alcohol intake (Figure 3c),
as well as alcohol preference (Supplementary Figure 2B).
Together, these results suggest that the long-lasting, but not
the immediate, effects of GDNF on alcohol consumption
depend on de novo protein synthesis.
Knockdown of GDNF expression in the VTA prevents the
long-lasting, but not the rapid, effects GDNF on alcohol
consumption. If the positive feedback loop of GDNF in the
VTA is the mechanism that underlies the long-lasting
suppressive effects of GDNF on alcohol intake, then
downregulation of GDNF in this region would prevent the
long-lasting, but not the immediate, effects of GDNF on
alcohol drinking. Rats were therefore trained in the
intermittent access to 20% alcohol, two-bottle choice
procedure for 7 weeks as described above. The VTA of the
rats was then infected with AdV-shGDNF or AdV-shSCR.
After a 3-day recovery period, rats were given three
additional drinking sessions to re-establish baseline alcohol
consumption. In the subsequent sessions, rGDNF or vehicle
was infused into the VTA 10min before the beginning of the
drinking session, and the immediate and extended effects of
GDNF on alcohol drinking were assessed. As shown in
Figure 4, intra-VTA infusion of rGDNF rapidly suppressed
alcohol consumption in the AdV-shSCR-infected rats
(Figure 4a), and the inhibition of alcohol intake was also
Figure 3 Inhibition of protein synthesis prevents the long-lasting, but not the acute, effects of recombinant glial cell line-derived neurotrophic factor (rGDNF) on alcohol
consumption. Rats consumed a solution of 20% alcohol for 7 weeks. Cycloheximide (CHX; 2 mg kg1, i.p.) was administered 1 h before and 3 h after the beginning of the
alcohol-drinking session. rGDNF (10 mg per side) was infused into the ventral tegmental area (VTA) 10 min before the beginning of the drinking session. (a) Timeline of
treatments and consumption measurements schedule. (a and b) Data are expressed as mean±s.e.m. of alcohol intake in g kg1 (*Po0.01 vs vehicle–vehicle; n¼ 12).
(b) Alcohol intake during the first 30 min of the drinking session (two-way repeated measurements analysis of variance (ANOVA): a main effect of rGDNF infusion
(F (1,13)¼ 34.79, Po0.0001), no effect of CHX pretreatment (F (1,13)¼ 1.28, P¼ 0.28), and no interaction (F (1,13)¼ 0.07, P¼ 0.79)). (c) Alcohol intake during the 4–24-h
time period after the beginning of the drinking session (two-way repeated measurements ANOVA: no effect of rGDNF infusion (F (1,13)¼ 2.19, P¼ 0.16), a significant main
effect of CHX pretreatment (F (1,13)¼ 10.46, Po0.007), and a significant interaction (F (1,13)¼ 13.16, Po0.005). Post-hoc comparisons: a significant difference between
rGDNF- and vehicle-infused rats in the vehicle control rats (Po0.01), but not in rats that were pretreated with CHX (P¼ 0.086)).
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present in the 4–24-h consumption period (Figure 4b and see
Supplementary Figure 3A). On its own, knockdown of GDNF
in the VTA had no effect on alcohol intake (Figure 4a),
preference (Supplementary Figure 3B) or on total fluid intake
(Supplementary Figure 3C). However, the downregulation
of GDNF expression level in the VTA prevented the long-
lasting inhibitory action of GDNF on alcohol consumption,
but spared the immediate, rapid effects of the growth
factor on alcohol intake (Figure 4b). These results suggest
that the long-lasting effects of GDNF on alcohol consumption
depend upon the initiation of GDNF-mediated transcription
within the VTA, and the consequent translation of the
growth factor.
Discussion
We report here that the administration of a single dose of
rGDNF into the VTA results in a robust local induction of the
growth factor’s own expression and protein synthesis,
resulting in a long-lasting activation of ERK1/2. We further
show that the long-lasting elevation in GDNF levels depends
upon de novo translation of this growth factor. These results
suggest that a single administration of rGDNF into the VTA
activates a positive autoregulatory feedback loop in which the
activation of the GDNF-mediated signaling pathway in the
VTA controls the expression of the growth factor (model,
Figure 5). Importantly, we show that a single treatment with
rGDNF produces a very long-lasting suppression of alcohol
drinking, which is maintained/sustained by the ability of
GDNF to positively autoregulate its own endogenous levels
in the VTA.
Positive autoregulation of GDNF mediates the long-
lasting suppression of alcohol consumption. We
previously found that activation of the GDNF pathway
within the VTA rapidly suppresses excessive alcohol
consumption.16,17 The rapid suppressive effects of GDNF
on alcohol consumption are mediated directly by the
exogenous rGDNF protein infused into the VTA, as they
were independent of the inhibition of GDNF translation.
These results, together with previous studies,7,18 imply that
the immediate effects of intra-VTA rGDNF infusion on alcohol
drinking are mediated by the exogenous rGDNF via a non-
genomic mechanism.
We also found that the suppressive actions of rGDNF on
alcohol are very long-lasting and are maintained for at least
48 h,16,17 and here we provide data to suggest that the GDNF-
mediated positive autoregulatory loop underlies the prolonged
suppressive effects of GDNF on alcohol consumption.
Specifically, we report that the long-lasting effects of a single
intra-VTA infusion of rGDNF on alcohol consumption are
prevented by the inhibition of protein synthesis, as well as by a
focal knockdown of the GDNF transcript in the VTA. Thus,
these prolonged effects depend upon the transcription and
translation of the endogenous polypeptide. It is possible,
therefore, that as long as the high levels of GDNF in the VTA
are maintained, alcohol seeking and consumption are
suppressed.
Knockdown of GDNF in the VTA prevented the long-lasting
suppression of alcohol intake by rGDNF; however, the
consumption of alcohol was unaffected by the downregulation
of the growth factor in control animals that did not receive
rGDNF. This result is puzzling, as activation of the
GDNF signaling in this brain region leads to suppression of
alcohol intake,16,17,26 and therefore, downregulation of the
GDNFmessage is expected to enhance alcohol consumption.
It should be borne in mind, however, that the basal levels of
GDNF in the VTA are very low,10,27 and therefore,
further downregulation of GDNF might not have significant
behavioral outcomes. Alternatively, it is plausible that the
negative result is due to a ceiling effect of alcohol intake, which
could not be further increased upon knockdown of the growth
factor.
GDNF positively autoregulates its own levels
in vivo. We found that intra-VTA infusion of rGDNF results
in a long-lasting upregulation of mRNA and protein levels of
the growth factor. Importantly, GDNF was not detected in
CHX-pretreated animals 24 h following the infusion of
the recombinant polypeptide into the VTA. CHX inhibits
the synthesis of de novo GDNF, but the drug cannot
alter the level of the exogenous recombinant polypeptide.
Figure 4 Downregulation of glial cell line-derived neurotrophic factor (GDNF) expression in the ventral tegmental area (VTA) prevents the sustained, but not the rapid,
effects of recombinant GDNF (rGDNF) on alcohol consumption. Rats consumed a solution of 20% alcohol for 7 weeks. After the establishment of a baseline level of alcohol
intake, VTA were infected with adenovirus (AdV)-shGDNF or control AdV-shSCR (SCR), after which the basal levels of alcohol intake were reestablished. Ten to 15 days after
the infection, rGDNF (10 mg per side) or vehicle was infused into the VTA 10 min before the drinking session onset. Data are expressed as mean±s.e.m. of alcohol intake in
g kg1 (*Po0.01 vs vehicle; n¼ 7). (a) Alcohol intake during the first 30 min of the drinking session (main effects of rGDNF infusion (F (1,12)¼ 40.55, Po0.0001) and of viral
infection (F (1,12)¼ 4.89, Po0.05), but no interaction (F (1,12)¼ 0.10, P¼ 0.75)). (b) Alcohol intake during the 4–24 h time period after the beginning of the drinking session
(mixed-model analysis of variance (ANOVA): a main effect of rGDNF infusion (F (1,12)¼ 6.67, Po0.025), no effect of viral infection (F (1,12)¼ 2.53, P¼ 0.13), and a
marginally significant interaction (F (1,12)¼ 3.88, P¼ 0.072). Post-hoc comparisons: a difference between rGDNF- and vehicle-infused rats in the adenovirus (AdV)-shSCR
infected control rats (Po0.01), but not in rats that were infected with AdV-shGDNF (P¼ 0.67)).
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Thus, the exogenous rGDNF was degraded after a 24-h
period, and therefore, the protein that was detected at this
stage was the endogenously synthesized GDNF. Moreover,
the long-lasting upregulation of GDNF expression that is
induced by a single infusion of the recombinant polypeptide
into the VTA is associated with a prolonged local activation of
Figure 5 A schematic illustration of the glial cell line-derived neurotrophic factor (GDNF) autoregulatory loop within the ventral tegmental area (VTA). (a) Recombinant
GDNF (rGDNF) binds to the GFRa1-Ret receptor complex in the VTA (1), which leads to the activation of Ret. Activation of the GDNF-mediated signaling pathway leads to the
upregulation of the transcription of the GDNF gene (2). GDNF mRNA is translated to GDNF protein, and secreted (3). Secreted GDNF binds to its receptor complex (4), and
activates its signaling pathway to maintain this positive feedback cycle. (b and c) Inhibition of protein synthesis by cycloheximide (CHX) (b) or adenovirus (AdV)-shGDNF-
mediated downregulation of GDNF in the VTA (c) disrupts the autoregulatory feedback cycle by reducing the level of endogenously-produced GDNF, thus preventing the
subsequent activation of the loop.
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ERK1/2, suggesting that this pathway is part of the positive
autoregulation cycle. Furthermore, as the increase in GDNF
levels and the activation of Ret-mediated signaling pathway
are detected within the same brain region, the autoregulatory
loop is likely to be autocrine and not paracrine.
Positive autoregulation of expression and secretion of
other neurotrophic factors has been demonstrated previously,
albeit only in in vitro cell culture systems. For example,
brain-derived neurotrophic factor positively regulates its own
expression,28,29 secretion30 and dendritic targeting of its own
mRNA31 in cortical and hippocampal cell cultures. Similarly,
nerve growth factor and neurotrophin-4 were shown to
increase their own expression in cortical cell cultures.29 We
provide here a unique demonstration that such a positive
autoregulatory cycle occurs in vivo. Therefore, these findings
may have significant implications for the function of other
growth factors. Moreover, the downstream effector genes
induced by the activation of the GDNF pathway are not well
characterized, and our findings illuminate an in vivo pathway
in which GDNF is its own effector gene.
At some point, however, the GDNF-mediated positive
feedback cycle is likely to be terminated. One possibility
is that long-term activation of GDNF signaling leads to a
reduced functionality of its receptors by their internalization,
degradation and/or ubiquitination. For example, Rap1GAP
(a GTPase-activating protein for Rap1) binds to the Ret
receptor, after the latter is activated by GDNF, and down-
regulates GDNF signaling.32 Similarly, dissociation of the
CD2-associated protein and the E3-ligase Cbl-3 from the Ret
receptor following the receptor’s autophosphorylation leads to
Ret degradation.33 Insufficient levels of Ret were shown to
trigger internalization of GFRa1 receptors.34 Therefore, it is
plausible that the positive and negative feedback loops of
GDNF co-exist and compete with each other to regulate the
levels of the growth factor. Specifically, whereas the levels of
GDNF mRNA are upregulated by the positive feedback loop,
the levels of the receptors are gradually reduced until they
reach critical levels that attenuate GDNF signaling, to an
extent that breaks the loop, and reduces the levels of the
growth factor.
Physiological function of the GDNF-mediated positive
autoregulatory loop. In the normal brain, within the
mesolimbic and nigrostriatal systems, the GDNF receptors
GFRa1 and Ret are highly expressed in the ventral midbrain,
namely, the substantia nigra and the VTA,8–10,20,21 whereas
the GDNF polypeptide itself is synthesized primarily in the
NAc/striatum.3,4 Conversely, the VTA and substantia nigra
normally express low basal levels of GDNF,10,27 and the
NAc/striatal-derived GDNF is retrogradely transported to the
midbrain through DA-ergic projections.3,5–7,35,36
This mechanism might change when the normal conditions
are disrupted. For example, damage to mesolimbic/nigros-
triatal neurons leads to increased level of GDNF in the ventral
midbrain.37–39 It is therefore plausible that under certain
conditions such as brain insult, this positive autoregulatory
mechanism has a role in the local amplification and prolonga-
tion of NAc-derived GDNF signaling. Once initiated, such a
mechanism can provide a stable and faster supply of the
growth factor, compared with the retrograde transportation of
GDNF from the striatum/NAc, which requires several hours.7
Potential implications. We show here that GDNF-
mediated positive regulation of its own levels occurs in vivo
in the VTA, a brain region where the actions of this growth
factor were shown to have significant effects on the
mesolimbic DA system.7,18 Our findings may have
important implications to the understanding of the func-
tion of GDNF in the midbrain, as well as to the regulation
of DA neurotransmission in the mesolimbic system.7,40
Furthermore, our results suggest pharmacological agents
that increase GDNF levels26,27,41,42 can evoke a prolonged
activation of the positive autoregulatory feedback loop, and
can therefore sustainably suppress excessive alcohol intake,
providing a long-lasting treatment strategy for alcohol use
and abuse disorders, and possibly for other drugs of
abuse.14,15
Specifically for alcohol, we previously showed that infusion
of rGDNF into the VTA reduces alcohol moderate and
excessive operant self-administration, as well as relapse to
alcohol drinking.17,18 More recently, we found that infusion of
rGDNF into the VTA normalizes chronic alcohol-induced DA
deficiency.19 Finally, we found that rGDNF prevents the
acquisition as well as the expression of alcohol-conditioned
place preference.18 Thus, this GDNF-mediated prolongation–
amplification mechanism might lead to a sustained suppres-
sion in the motivation to seek alcohol and/or in the rewarding
properties of the latter.
In addition, it is highly likely that our findings are relevant to
the effects of GDNF on self-administration of other drugs of
abuse.14,15 For example, an activation of the GDNF pathway
in the striatum decreases cocaine self-administration.43,44
Furthermore, a single intra-VTA rGDNF infusion after self-
administration was reported to increase cue-induced cocaine
seeking on withdrawal days 3 and 10 (‘incubation of cocaine
craving’).45 Although it was previously suggested GDNF may
cause differential effects depending on the timing of admin-
istration (i.e., before or after drug self-administration),15 it is
also plausible that this long-term effect is also mediated by the
capacity of a single rGDNF administration to maintain high
levels of the growth factor in the VTA via the positive
autoregulatory loop.
Importantly, increases in the growth factor have been
proposed as a promising treatment strategy for Parkinson’s
disease,12,46–48 and reduced levels of GDNF have recently
been implicated also in chronic stress.13 Therefore, our
findings that exogenous activation of the GDNF pathway
leads to a sustained upregulation of the growth factor in vivo
may have beneficial implications for the development of
treatments for Parkinson’s disease and chronic stress.
Conflict of interest
The authors declare no conflict of interest.
Acknowledgements. This research was supported by funds provided by
the National Institutes of Health–National Institute on Alcohol Abuse and Alcoholism
(NIH–NIAAA) RO1 AA014366 (DR), the State of California for Medical Research on
Positive autoregulatory loop of GDNF in the VTA
S Barak et al
8
Translational Psychiatry
Alcohol and Substance Abuse through the University of California San Francisco
(DR), NIH–NIAAA Predoctoral Fellowship F31 AA017801 (SA), NIH Training Grant
T32 GM007175 (SA), and Merck Laboratories Research Fellow award (SA). We
thank Dr Sebastien Carnicella for the critical review of this manuscript.
1. Lin LF, Doherty DH, Lile JD, Bektesh S, Collins F. GDNF: a glial cell line-derived
neurotrophic factor for midbrain dopaminergic neurons. Science 1993; 260: 1130–1132.
2. Airaksinen MS, Saarma M. The GDNF family: signalling, biological functions and
therapeutic value. Nat Rev Neurosci 2002; 3: 383–394.
3. Barroso-Chinea P, Cruz-Muros I, Aymerich MS, Rodriguez-Diaz M, Afonso-Oramas D,
Lanciego JL et al. Striatal expression of GDNF and differential vulnerability of midbrain
dopaminergic cells. Eur J Neurosci 2005; 21: 1815–1827.
4. Pochon NA, Menoud A, Tseng JL, Zurn AD, Aebischer P. Neuronal GDNF expression
in the adult rat nervous system identified by in situ hybridization. Eur J Neurosci 1997; 9:
463–471.
5. Tomac A, Widenfalk J, Lin LF, Kohno T, Ebendal T, Hoffer BJ et al. Retrograde axonal
transport of glial cell line-derived neurotrophic factor in the adult nigrostriatal system
suggests a trophic role in the adult. Proc Natl Acad Sci USA 1995; 92: 8274–8278.
6. Kordower JH, Emborg ME, Bloch J, Ma SY, Chu Y, Leventhal L et al. Neurodegeneration
prevented by lentiviral vector delivery of GDNF in primate models of Parkinson0s disease.
Science 2000; 290: 767–773.
7. Wang J, Carnicella S, Ahmadiantehrani S, He DY, Barak S, Kharazia V et al.
Nucleus accumbens-derived glial cell line-derived neurotrophic factor is a retrograde
enhancer of dopaminergic tone in the mesocorticolimbic system. J Neurosci 2010; 30:
14502–14512.
8. Burazin TC, Gundlach AL. Localization of GDNF/neurturin receptor (c-ret, GFRalpha-1 and
alpha-2) mRNAs in postnatal rat brain: differential regional and temporal expression in
hippocampus, cortex and cerebellum. Brain Res Mol Brain Res 1999; 73: 151–171.
9. Matsuo A, Nakamura S, Akiguchi I. Immunohistochemical localization of glial cell line-
derived neurotrophic factor family receptor alpha-1 in the rat brain: confirmation of
expression in various neuronal systems. Brain Res 2000; 859: 57–71.
10. Trupp M, Belluardo N, Funakoshi H, Ibanez CF. Complementary and overlapping
expression of glial cell line-derived neurotrophic factor (GDNF), c-ret proto-oncogene, and
GDNF receptor-alpha indicates multiple mechanisms of trophic actions in the adult rat
CNS. J Neurosci 1997; 17: 3554–3567.
11. Sariola H, Saarma M. Novel functions and signalling pathways for GDNF. J Cell Sci 2003;
116(Part 19): 3855–3862.
12. Sherer TB, Fiske BK, Svendsen CN, Lang AE, Langston JW. Crossroads in GDNF therapy
for Parkinson’s disease. Mov Disord 2006; 21: 136–141.
13. Uchida S, Hara K, Kobayashi A, Otsuki K, Yamagata H, Hobara T et al. Epigenetic status of
Gdnf in the ventral striatum determines susceptibility and adaptation to daily stressful
events. Neuron 2011; 69: 359–372.
14. Carnicella S, Ron D. GDNF—a potential target to treat addiction. Pharmacol Ther 2009;
122: 9–18.
15. Ghitza UE, Zhai H, Wu P, Airavaara M, Shaham Y, Lu L. Role of BDNF and GDNF in drug
reward and relapse: A review. Neurosci Biobehav Rev 2009; 157–171.
16. Carnicella S, Amamoto R, Ron D. Excessive alcohol consumption is blocked by glial cell
line-derived neurotrophic factor. Alcohol 2009; 43: 35–43.
17. Carnicella S, Kharazia V, Jeanblanc J, Janak PH, Ron D. GDNF is a fast-acting
potent inhibitor of alcohol consumption and relapse. Proc Natl Acad Sci USA 2008; 105:
8114–8119.
18. Barak S, Carnicella S, Yowell QV, Ron D. Glial cell line-derived neurotrophic factor
reverses alcohol-induced allostasis of the mesolimbic dopaminergic system: implications
for alcohol reward and seeking. J Neurosci 2011; 31: 9885–9894.
19. He DY, Ron D. Autoregulation of glial cell line-derived neurotrophic factor expression:
implications for the long-lasting actions of the anti-addiction drug, Ibogaine. FASEB J 2006;
20: 2420–2422.
20. Golden JP, Baloh RH, Kotzbauer PT, Lampe PA, Osborne PA, Milbrandt J et al.
Expression of neurturin, GDNF, and their receptors in the adult mouse CNS. J Comp
Neurol 1998; 398: 139–150.
21. Glazner GW, Mu X, Springer JE. Localization of glial cell line-derived neurotrophic factor
receptor alpha and c-ret mRNA in rat central nervous system. J Comp Neurol 1998; 391:
42–49.
22. Obrig TG, Culp WJ, McKeehan WL, Hardesty B. The mechanism by which cycloheximide
and related glutarimide antibiotics inhibit peptide synthesis on reticulocyte ribosomes. J Biol
Chem 1971; 246: 174–181.
23. Siegel MR, Sisler HD. Inhibition of protein synthesis in vitro by cycloheximide. Nature 1963;
200: 675–676.
24. Milekic MH, Brown SD, Castellini C, Alberini CM. Persistent disruption of an established
morphine conditioned place preference. J Neurosci 2006; 26: 3010–3020.
25. National_Institute_on_Alcohol_Abuse_and_Alcoholism (NIAAA). Council approves defini-
tion of binge drinking. NIAAA Newsletter 2004; 3.
26. Carnicella S, Ahmadiantehrani S, He DY, Nielsen CK, Bartlett SE, Janak PH et al.
Cabergoline decreases alcohol drinking and seeking behaviors via glial cell line-derived
neurotrophic factor. Biol Psychiatry 2009; 66: 146–153.
27. He DY, McGough NN, Ravindranathan A, Jeanblanc J, Logrip ML, Phamluong K et al.
Glial cell line-derived neurotrophic factor mediates the desirable actions of the anti-
addiction drug ibogaine against alcohol consumption. J Neurosci 2005; 25: 619–628.
28. Xiong H, Futamura T, Jourdi H, Zhou H, Takei N, Diverse-Pierluissi M et al. Neurotrophins
induce BDNF expression through the glutamate receptor pathway in neocortical neurons.
Neuropharmacology 2002; 42: 903–912.
29. Patz S, Wahle P. Neurotrophins induce short-term and long-term changes of cortical
neurotrophin expression. Eur J Neurosci 2004; 20: 701–708.
30. Canossa M, Griesbeck O, Berninger B, Campana G, Kolbeck R, Thoenen H. Neurotrophin
release by neurotrophins: implications for activity-dependent neuronal plasticity. Proc Natl
Acad Sci USA 1997; 94: 13279–13286.
31. Righi M, Tongiorgi E, Cattaneo A. Brain-derived neurotrophic factor (BDNF) induces
dendritic targeting of BDNF and tyrosine kinase B mRNAs in hippocampal neurons through
a phosphatidylinositol-3 kinase-dependent pathway. J Neurosci 2000; 20: 3165–3174.
32. Jiao L, Zhang Y, Hu C, Wang YG, Huang A, He C. Rap1GAP interacts with RET and
suppresses GDNF-induced neurite outgrowth. Cell Res 2011; 21: 327–337.
33. Tsui CC, Pierchala BA. CD2AP and Cbl-3/Cbl-c constitute a critical checkpoint in the
regulation of ret signal transduction. J Neurosci 2008; 28: 8789–8800.
34. Vieira P, Thomas-Crusells J, Vieira A. Internalization of glial cell-derived neurotrophic factor
receptor GFR alpha 1 in the absence of the ret tyrosine kinase coreceptor. Cell Mol
Neurobiol 2003; 23: 43–55.
35. Ai Y, Markesbery W, Zhang Z, Grondin R, Elseberry D, Gerhardt GA et al. Intraputamenal
infusion of GDNF in aged rhesus monkeys: distribution and dopaminergic effects. J Comp
Neurol 2003; 461: 250–261.
36. Lapchak PA, Jiao S, Collins F, Miller PJ. Glial cell line-derived neurotrophic factor:
distribution and pharmacology in the rat following a bolus intraventricular injection. Brain
Res 1997; 747: 92–102.
37. Mandel S, Grunblatt E, Maor G, Youdim MB. Early and late gene changes in MPTP mice
model of Parkinson0s disease employing cDNA microarray. Neurochem Res 2002; 27:
1231–1243.
38. Yurek DM, Fletcher-Turner A. Temporal changes in the neurotrophic environment of the
denervated striatum as determined by the survival and outgrowth of grafted fetal dopamine
neurons. Brain Res 2002; 931: 126–134.
39. Grunblatt E, Mandel S, Maor G, Youdim MB. Gene expression analysis in N-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine mice model of Parkinson’s disease using cDNA
microarray: effect of R-apomorphine. J Neurochem 2001; 78: 1–12.
40. Yang F, Feng L, Zheng F, Johnson SW, Du J, Shen L et al. GDNF acutely modulates
excitability and A-type K(+) channels in midbrain dopaminergic neurons. Nat Neurosci
2001; 4: 1071–1078.
41. Carnicella S, He DY, Yowell QV, Glick SD, Ron D. Noribogaine, but not 18-MC, exhibits
similar actions as ibogaine on GDNF expression and ethanol self-administration. Addict
Biol 2010; 15: 424–433.
42. Saavedra A, Baltazar G, Duarte EP. Driving GDNF expression: the green and the red traffic
lights. Prog Neurobiol 2008; 86: 186–215.
43. Green-Sadan T, Kinor N, Roth-Deri I, Geffen-Aricha R, Schindler CJ, Yadid G.
Transplantation of glial cell line-derived neurotrophic factor-expressing cells into the
striatum and nucleus accumbens attenuates acquisition of cocaine self-administration in
rats. Eur J Neurosci 2003; 18: 2093–2098.
44. Green-Sadan T, Kuttner Y, Lublin-Tennenbaum T, Kinor N, Boguslavsky Y, Margel S et al.
Glial cell line-derived neurotrophic factor-conjugated nanoparticles suppress acquisition of
cocaine self-administration in rats. Exp Neurol 2005; 194: 97–105.
45. Lu L, Wang X, Wu P, Xu C, Zhao M, Morales M et al. Role of ventral tegmental area glial
cell line-derived neurotrophic factor in incubation of cocaine craving. Biol Psychiatry 2009;
66: 137–145.
46. Hong M, Mukhida K, Mendez I. GDNF therapy for Parkinson’s disease. Expert Rev
Neurother 2008; 8: 1125–1139.
47. Xia CF, Boado RJ, Zhang Y, Chu C, Pardridge WM. Intravenous glial-derived neurotrophic
factor gene therapy of experimental Parkinson0s disease with Trojan horse liposomes and
a tyrosine hydroxylase promoter. J Gene Med 2008; 10: 306–315.
48. Manfredsson FP, Okun MS, Mandel RJ. Gene therapy for neurological disorders:
challenges and future prospects for the use of growth factors for the treatment of
Parkinson0s disease. Curr Gene Ther 2009; 9: 375–388.
Translational Psychiatry is an open-access journal
published by Nature Publishing Group. This work is
licensed under the Creative Commons Attribution-Noncommercial-No
Derivative Works 3.0 Unported License. To view a copy of this license,
visit http://creativecommons.org/licenses/by-nc-nd/3.0/
Supplementary Information accompanies the paper on the Translational Psychiatry website (http://www.nature.com/tp)
Positive autoregulatory loop of GDNF in the VTA
S Barak et al
9
Translational Psychiatry
